Multimodal Spatial Biology Analysis Platforms Market (2026 - 2033)

Multimodal Spatial Biology Analysis Platforms Market Summary

The global multimodal spatial biology analysis platforms market size was valued at USD 241.5 million in 2025 and is projected to grow from USD 289.9 million in 2026 to USD 1,086.7 million by 2033, at a CAGR of 20.8% from 2026 to 2033. The market in North America dominated with a revenue share of 55.0% in 2025. The market growth is driven by increasing adoption of spatial transcriptomics and proteomics technologies, growing demand for integrated biological analysis, and expanding applications of tissue mapping in cancer research, precision medicine, and drug development.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

The multimodal spatial biology analysis platforms industry is witnessing significant growth, driven by increasing demand for spatially resolved biological analysis across cancer research, precision medicine, biomarker discovery, and drug development. Growing adoption of spatial transcriptomics, spatial proteomics, and advanced imaging technologies is enabling researchers to characterize gene expression, protein distribution, and tissue architecture while preserving spatial context. In addition, expanding integration of multiomics datasets, artificial intelligence, and computational analysis for understanding cellular interactions, tumor microenvironments, disease mechanisms, and therapeutic responses is supporting market growth.

Market Concentration & Characteristics

The degree of innovation in the multimodal spatial biology analysis platforms market is high, driven by advances in spatial omics integration, AI-based analytics, and tissue imaging. For instance, in April 2025, PredxBio launched enhanced capabilities for its SpaceIQ platform, enabling the integration of brightfield imaging, spatial proteomics, and transcriptomics datasets within a unified analytical framework. The platform uses AI-driven spatial analysis to characterize cellular interactions and the tumor microenvironment, supporting biomarker discovery, patient stratification, and precision oncology research.

The industry is witnessing strategic acquisitions as companies expand their spatial analysis capabilities. For instance, in July 2023, Bio-Techne Corporation completed the acquisition of Lunaphore Technologies SA, a developer of automated spatial biology solutions. Lunaphore’s portfolio includes the COMET platform, which integrates tissue staining, imaging, and image preprocessing into an automated, high-throughput system capable of analyzing up to 40 spatial biomarkers per sample in each run. The acquisition expanded Bio-Techne’s spatial biology portfolio, strengthening its capabilities in tissue profiling for translational and clinical research.

To learn more about this report, Download Free Sample Report

The impact of regulations on the market is moderate, as regulatory expectations for digital imaging, analytical performance, and clinical research data quality influence the development and application of these platforms. For instance, in January 2025, the U.S. Food and Drug Administration (FDA) issued draft guidance on Developing Drugs for Optical Imaging, outlining recommendations for clinical trial design involving imaging drugs used with imaging devices. Although this guidance does not specifically regulate spatial biology analysis platforms, it highlights the importance of reliable imaging data and appropriate validation when imaging technologies are used in clinical development.

he market is expanding through the launch of instruments that combine spatial molecular imaging with integrated data visualization and analysis. For instance, in June 2024, Bruker Corporation launched the neofleX MALDI-TOF/TOF system for mass spectrometry imaging of tissue samples. Compatible with Bruker’s MALDI HiPLEX-IHC and AmberGen’s MALDI-ISH workflows, the system supports spatial analysis of proteins, lipids, glycans, metabolites, peptides, and RNA/DNA targets. Its associated SCiLS Scope software enables visualization of imaging data, supporting multimodal spatial tissue research in oncology, neuroscience, and translational medicine.

“The neofleX offers unique combination of outstanding performance, multimodal software and workflows on the benchtop for a wide range of biopharma and clinical researchers. Additionally, neofleX brings novel capabilities to spatial biology, including spatial proteomics combined with unique multiomics correlations for developing actionable biological insights.”

- Dr. Michael L. Easterling, Vice President MSI for Bruker’s Life Sciences Mass Spectrometry division

The market is witnessing regional expansion as companies strengthen their manufacturing and operational infrastructure to meet growing demand for spatial biology technologies. For instance, in May 2024, Akoya Biosciences opened an Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts, United States. The 32,000-square-foot facility houses research and development, manufacturing, quality control, warehousing, and distribution operations, with a primary focus on producing molecularly barcoded antibodies and related reagents for its spatial biology platforms. This expansion strengthens production capacity and supports the supply of spatial biology solutions to research and clinical customers.

“Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to understand biology, disease progression, and patients’ response to therapy. The vast potential of spatial biology, combined with the higher throughput and plex capabilities of our systems, are driving increased demand for our reagents. We expect our investment in the Manufacturing Center of Excellence will drive operational efficiencies, allowing us to better serve our customers, deliver reagents at increasing scale, and further broaden our portfolio of reagents to unlock new market opportunities.”

- Brian McKelligon, CEO of Akoya Biosciences.

Analyst Perspective

The multimodal spatial biology analysis platforms market is expected to witness high growth, supported by increasing demand for integrated molecular analysis that preserves spatial information within biological tissues. As researchers seek deeper insights into disease mechanisms, cellular interactions, and tissue microenvironments, demand is expected to rise for platforms combining spatial transcriptomics, proteomics, advanced imaging, and multiomics data analysis. Growing applications in cancer research, biomarker discovery, precision medicine, and drug development are further supporting market expansion. However, high implementation costs and complex data integration requirements may limit broader adoption. Market participants are focusing on improving analytical capabilities, integrating AI-driven software, enhancing platform throughput, and developing three-dimensional spatial analysis solutions.

Offering Insights

The consumables & reagents segment accounted for the largest revenue share, over 59.4% in 2025, supported by increasing demand for specialized assay kits, antibody panels, probes, and amplification reagents used in spatial proteomics and transcriptomics. These products enable researchers to detect multiple molecular targets while preserving tissue architecture and cellular context. For instance, in March 2026, Bio-Techne expanded its COMET spatial biology portfolio with new SPYRE Focus Panels targeting stromal and vascular markers and SPYRE Amplification Kits designed to improve the detection of low-abundance targets. This expansion highlights continued innovation in specialized reagents and consumables for multiplexed spatial biology workflows.

“Researchers need tools that make it easier to extract meaningful answers from complex tissue samples. Innovation is one of Bio-Techne's key differentiators, and SPYRE Focus Panels and SPYRE Amplification Kits reflect that strength. By incorporating these capabilities into the COMET Suite, we are giving researchers a more flexible, faster, and higher sensitivity workflow that enables researchers to achieve deeper insights with greater confidence.”

- Steve Crouse, President of Bio-Techne's Diagnostics and Spatial Biology Segment.

The software segment is expected to register the fastest CAGR during 2026-2033, driven by increasing complexity of spatial omics datasets and the need for integrated tools to visualize, process, and interpret multimodal biological information. These software solutions enable researchers to integrate spatial transcriptomics, proteomics, histology, and other molecular datasets to investigate cellular interactions and tissue architecture. For instance, in May 2026, Advaita Bio launched its iSCanGuide platform, a cloud-based analysis solution that integrates single-cell and spatial transcriptomics workflows with pathway analysis and cell-to-cell communication analysis. This development highlights the growing adoption of integrated software tools to streamline spatial data analysis and support biological discovery.

“Researchers are drowning in data and starving for insight. iSCanGuide collapses what used to be a weeks-long manual process into minutes - from count matrices to annotated cell types, spatial context, and mechanistic pathway analysis in a single platform.”

- Mike Mattacola, CEO of Advaita Bio

Modality Combination Insights

The transcriptomics + proteomics segment dominated the market with a share of 69.6% in 2025, supported by increasing demand for integrated analysis of gene expression and protein activity within their native tissue environment. Combining these modalities enables researchers to characterize cellular functions, tissue organization, and disease-associated molecular interactions more comprehensively. For instance, in August 2025, 10x Genomics launched Xenium Protein, an addition to its Xenium Spatial platform that enables simultaneous detection of RNA and proteins in the same cells and tissue section in a single automated run. This development highlights advances in integrated spatial multiomics solutions and supports the adoption of transcriptomics and proteomics combination workflows in biological and disease research.

"Scientists can now analyze RNA and protein together, streamlining workflows, removing the need for complex data integration and unlocking more precise insights. Integrated multiomic analysis is essential to advancing our understanding of complex diseases and accelerating therapeutic discovery."

- Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics.

The transcriptomics + genomics / epigenomics segment is expected to register the fastest CAGR during 2026-2033, driven by increasing demand for integrated molecular profiling to understand gene expression, genetic variation, and epigenetic regulation within their spatial tissue context. Combining these modalities enables researchers to investigate cellular heterogeneity, gene regulatory mechanisms, and disease-associated molecular changes while preserving tissue architecture. The growing adoption of spatial multiomics approaches in cancer research, developmental biology, and disease profiling is expected to support demand for platforms capable of integrating transcriptomic and genomic or epigenomic data.

Technology Insights

The imaging-based segment accounted for approximately 61.1% of the technology segment in 2025, mainly due to advances in multiplexed imaging, automated microscopy, and in situ molecular detection technologies. These platforms enable researchers to visualize and quantify multiple molecular targets while preserving tissue architecture and cellular relationships. For instance, in September 2026, Leica Microsystems launched the Autiva Spatial Phenotyper, an imaging-based spatial biology platform integrating automated staining, multiplex imaging, reagents, and AI-powered image analysis. The platform supports automated cyclic staining and imaging, enabling researchers to characterize cellular phenotypes and tissue interactions in complex samples. This development highlights ongoing innovation in imaging-based technologies for spatial biology research.

“By combining our imaging excellence with intelligent automation, an expanding reagent ecosystem, and AI-enabled analysis, Autiva Spatial Phenotyper helps researchers transform complex tissue biology into meaningful spatial insights. The platform enables laboratories to characterize tissue phenotypes with greater efficiency and consistency, accelerating biomarker discovery, translational research, and the development of next-generation therapies”

- Nicolas Pierre, Vice President and General Manager Life Science and Applied Solutions at Leica Microsystems.

Sequencing-based segment is projected to register the fastest CAGR during 2026-2033, driven by increasing demand for high-throughput molecular profiling and comprehensive gene expression analysis within intact tissue samples. These platforms use next-generation sequencing (NGS), spatial barcoding, and specialized computational tools to map gene expression while preserving spatial information. Integration with other omics datasets, including proteomics and epigenomics, enables researchers to investigate cellular heterogeneity, tissue organization, and disease-associated molecular changes. Growing applications in oncology, drug discovery, and translational research are expected to support the adoption of sequencing-based spatial biology analysis platforms.

Sample Type Insights

The FFPE tissue segment accounted for the largest revenue share, over 57.6% in 2025, supported by increasing use of archived tissue specimens in cancer research, biomarker discovery, and translational studies. FFPE samples preserve tissue morphology and enable researchers to analyze gene expression and protein distribution within their spatial context. According to an article published in Cancer Research Communications in August 2026, researchers demonstrated an integrated workflow for sequential RNA and protein profiling in FFPE tumor tissue. This development highlights the potential of FFPE samples for combined spatial transcriptomic and proteomic analysis, supporting their use in comprehensive tumor characterization and disease research.

The fresh frozen tissue segment is expected to register the fastest CAGR during 2026-2033, driven by suitability of fresh frozen samples for preserving RNA integrity and supporting comprehensive molecular profiling. These samples enable researchers to investigate spatial gene expression, cellular heterogeneity, and tissue organization across applications such as oncology, neuroscience, and drug discovery. For instance, in May 2025, 10x Genomics launched its Visium HD 3′ Gene Expression assay, a high-resolution spatial transcriptomics solution compatible with fresh frozen tissues. The assay supports whole-transcriptome analysis across multiple species while retaining spatial context, highlighting advances in spatial profiling technologies for fresh frozen biological samples.

“Visium HD 3' is designed to help researchers explore the unknown. Whether you're working in rat, non-human primate or other emerging models, this new assay empowers spatial discovery in ways never before possible - with no compromise to resolution or data quality.”

- Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics

Application Insights

The oncology segment dominated the market with a share of 45.2% in 2025, supported by increasing use of spatial molecular profiling to study tumor heterogeneity, characterize the tumor microenvironment, and identify cancer biomarkers. These platforms enable integrated analysis of gene expression, protein distribution, and cellular interactions within tumor tissues. For instance, in March 2026, Bioptimus announced STELA, a multimodal spatial biology initiative developed with 10x Genomics and Broad Clinical Labs to profile up to 100,000 patient specimens, initially focusing on oncology and immunology. The initiative aims to integrate spatial omics, pathology imaging, and clinical data to support cancer research and biomarker discovery.

The immunology & inflammation segment is expected to register the fastest CAGR during 2026-2033, driven by increasing use of spatial molecular profiling to investigate immune cell populations, inflammatory pathways, and cell-to-cell interactions within tissues. These platforms enable researchers to integrate spatial transcriptomics and proteomics data to understand immune responses and characterize disease mechanisms. Growing applications in autoimmune disorders, chronic inflammatory diseases, infectious diseases, and immunotherapy research are expected to support demand for multimodal spatial biology analysis platforms.

End Use Insights

Academic & translational research institutes segment accounted for approximately 47.5% share in 2025, making it a leading end use segment. Growth is driven by increasing research into disease mechanisms, cellular interactions, and biomarker discovery. These institutions use spatial biology platforms to integrate molecular data with tissue architecture, supporting basic research and the translation of scientific findings into potential diagnostic and therapeutic applications. For instance, in September 2024, the Translational Genomics Research Institute (TGen), part of City of Hope, launched the Center for Spatial Multi-Omics (COSMO), a dedicated service center offering spatial biology technologies to help researchers map molecular data at single-cell and subcellular resolution. This initiative highlights the growing adoption of specialized spatial analysis infrastructure to support academic and translational biomedical research.

To learn more about this report, Download Free Sample Report

Pharmaceutical & biotechnology companies segment is projected to witness the fastest CAGR during 2026-2033, supported by increasing investments in drug discovery, biomarker identification, and precision medicine. These companies use spatial biology platforms to study tissue heterogeneity, characterize tumor microenvironments, validate therapeutic targets, and evaluate treatment responses. The integration of spatial transcriptomics and proteomics helps researchers better understand disease mechanisms and drug activity, supporting the development of targeted therapies and improving preclinical research.

Regional Insights

North America dominated the multimodal spatial biology analysis platforms market accounting for the largest revenue share of 55.0% in 2025, driven by development in spatial transcriptomics and the integration of molecular data with tissue architecture. For instance, in February 2025, Illumina announced a new spatial transcriptomics technology and expanded its software portfolio with Illumina Connected Multiomics. The technology combines whole-transcriptome profiling at cellular resolution with multimodal data analysis, enabling researchers to investigate cellular interactions and tissue organization. This development supports spatial biology research in oncology, neuroscience, and drug discovery.

"Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms. Illumina spatial technology will deliver another complete workflow on our leading sequencing platforms. With this innovation, we are setting a new bar that will drive the next wave of scientific discoveries and unlock a deeper understanding of biology-from the impact of cell interactions on disease to the mechanisms needed to solve them."

- Steve Barnard, PhD, chief technology officer of Illumina.

To learn more about this report, Download Free Sample Report

U.S. Multimodal Spatial Biology Analysis Platforms Market Trends

The U.S. multimodal spatial biology analysis platforms market is expected to grow over the forecast period, supported by advances in spatial transcriptomics, proteomics, and integrated analysis of tissue-level molecular data. For instance, in February 2026, U.S.-based Singular Genomics announced the commercial launch of its G4X platform in the United States. The platform simultaneously analyzes up to 500 RNA targets and 18 protein markers while incorporating fluorescence-based tissue imaging, enabling subcellular-resolution spatial multiomics. This launch expands commercial access to integrated spatial analysis for translational research, spatial pathology, and drug development.

“The launch of G4X reflects a clear inflection point for spatial. With the performance, scale, and affordability we’ve demonstrated, spatial analysis can now move beyond boutique experiments to power large cohorts, translational pipelines, and AI model development. We believe this is the foundation for the next wave of spatial pathology, one defined by clinical relevance, statistical power, and real-world impact.”

-Josh Stahl, CEO of Singular

Europe Multimodal Spatial Biology Analysis Platforms Market Trends

Europe multimodal spatial biology analysis platforms market is anticipated to grow significantly over the forecast period, supported by collaborations between spatial biology technology providers and European research institutions to expand access to advanced tissue-analysis tools. For instance, in June 2026, MGI Tech launched its Go Spatial workflow in Europe at the STOC general meeting in Milan, Italy, and welcomed Germany-based Omics Empower GmbH as a certified STOmics service provider. Built on Stereo-seq technology, Go Spatial supports high-resolution spatial transcriptomics across large tissue areas, helping researchers investigate tissue organization and gene-expression patterns for oncology, neuroscience, and other life-science applications.

"STOC 2026 is an important opportunity to connect with the global spatial biology community and support the collaborative work needed to move the field forward. With Go Spatial and Omics Empower as a new STOmics certified service provider, MGI is strengthening both the technology and service ecosystem for spatial transcriptomics in Europe."

- Fang Chen, Vice President of MGI and General Manager of Europe & Africa at MGI

The U.K. multimodal spatial biology analysis platforms industry is expected to grow over the forecast period, driven by research collaborations adopting advanced spatial proteomics technologies for cancer research. For instance, in October 2024, Akoya Biosciences announced that its PhenoCycler-Fusion and PhenoImager HT platforms had been selected for the UK-based MANIFEST initiative, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust. Funded by the UK Office for Life Sciences and the Medical Research Council, the four-year initiative will use the platforms to profile cancer tissue samples and investigate biomarkers associated with immunotherapy response and toxicity across thousands of patients. This collaboration highlights the application of spatial proteomics platforms in clinical research and biomarker discovery.

The multimodal spatial biology analysis platforms market in Germany is witnessing growth through strategic collaborations aimed at developing integrated single-cell and multi-omics technologies. For instance, in July 2024, the Max Delbrück Center in Berlin announced a €1.2 million (USD 1.6 million) research and development collaboration with Bruker to establish the MDC-Bruker Center of Excellence for Single Cell Omics. Supported by the Helmholtz Association, with Bruker co-financing 20% of the project, the initiative aims to develop a multi-omics platform capable of simultaneously profiling proteins, metabolites, and lipids to investigate disease processes at single-cell resolution. This collaboration supports advances in multimodal spatial biology analysis and precision medicine research in Germany.

“Through innovations in ultrasensitive mass spectrometry, the proteomics research field has made a significant leap forward in recent years to measure single-cell proteomes at unprecedented biological resolution. This is an excellent foundation for our planned activities to further develop this technology for multi-omics approaches and to gain deeper insights into health and disease states.”

-Dr. Fabian Coscia, head of the Spatial Proteomics Group at the Max Delbrück Center and member of the MDC-Bruker core team

Asia Pacific Multimodal Spatial Biology Analysis Platforms Market Trends

Asia Pacific is expected to grow at the fastest CAGR of 23.0% during the forecast period, supported by research institutions, biotechnology companies, and healthcare organizations increasingly adopt spatial transcriptomics, spatial proteomics, advanced tissue imaging, and integrated multi-omics analysis to investigate disease mechanisms at cellular resolution. Rising investment in precision medicine, cancer research, drug discovery, and life sciences infrastructure is expected to support regional demand for technologies that combine molecular information with tissue architecture. Moreover, expanding collaborations between academic institutions and biotechnology companies, alongside growing research capabilities in Asia Pacific countries, are creating opportunities for spatial biology analysis platforms in biomarker discovery, disease research, and translational medicine.

China’s multimodal spatial biology analysis platforms market is advancing through collaborations that integrate multiple molecular data types to improve spatial analysis of biological tissues. For instance, in May 2024, STOmics and Shanghai-based Zhongke Xinsheng (APTBIO) announced a collaboration combining spatial transcriptomics with spatial proteomics and spatial metabolomics to enable integrated analysis of gene expression, protein distribution, and metabolic activity in tissue samples. By combining data from adjacent tissue sections while preserving spatial context, the collaboration supports more comprehensive investigations of disease mechanisms and biomarker discovery, strengthening China’s capabilities in multimodal spatial biology research.

"We believe that through our multi-faceted and multi-channel cooperation and promotion, we will surely be able to build a high-level exchange and cooperation platform for researchers and industry professionals, gather wisdom and strength for the development of space multi-omics, and further promote the innovation, theoretical research and industrial upgrading of global omics technologies. Let us take mass spectrometry as our starting point, continuously innovate omics technologies, accumulate knowledge and experience, and look forward to the fruitful results of spatiotemporal omics in the field of precision medicine, creating infinite possibilities!"

-Li Pengpeng, General Manager of the Technology Services Division, Shanghai Zhongke New Life Biotechnology Co., Ltd.

Japan’s multimodal spatial biology analysis platforms market is witnessing rapid growth driven by increasing research into cancer biology, precision medicine, and integrated multi-omics technologies. For instance, according to an abstract published in Cancer Research in April 2025, the SCRUM-Japan MONSTAR-SCREEN-3 study combines high-resolution spatial transcriptomics with circulating tumor DNA/RNA sequencing, tissue genomic analysis, plasma proteomics, and microbiome analysis to investigate tumor microenvironment dynamics across cancer types. This initiative supports the advancement of multimodal spatial biology research in Japan by enabling integrated analysis of spatial and molecular data.

Latin America Multimodal Spatial Biology Analysis Platforms Market Trends

The Latin America multimodal spatial biology analysis platforms industry is expected to grow steadily over the forecast period, supported by increasing adoption of spatial transcriptomics, spatial proteomics, advanced tissue imaging, and integrated multi-omics approaches across academic and biomedical research institutions. Growing interest in cancer research, infectious diseases, precision medicine, and biomarker discovery supports the demand for technologies that combine molecular data with tissue architecture and cellular location. Moreover, regional efforts to strengthen research infrastructure, expand scientific collaboration, and improve access to advanced analytical technologies are creating opportunities for spatial biology platforms in disease research, drug development, and translational medicine.

MEA Multimodal Spatial Biology Analysis Platforms Market Trends

The Middle East & Africa multimodal spatial biology analysis platforms market is growing steadily, supported by increasing investment in biomedical research, rising adoption of spatial transcriptomics and spatial proteomics, and growing demand for integrated multi-omics analysis. Expanding research into cancer, infectious diseases, and immune-related disorders is increasing the need for platforms that combine molecular profiling with tissue imaging and spatial data analysis. In addition, improvements in research infrastructure, growing collaborations between academic institutions and biotechnology companies, and increasing interest in precision medicine are expected to support market adoption across the region.

Key Companies & Market Share Insights

The multimodal spatial biology analysis platforms market is highly competitive, with key players focusing on spatial transcriptomics, proteomics, multiomics integration, high-resolution imaging, sequencing technologies, and advanced bioinformatics solutions. Companies are strengthening their market position through product launches, technological advancements, strategic collaborations, and expansion of spatial analysis capabilities. Moreover, competitive positioning depends on platform offerings, technological capabilities, data accuracy, geographic presence, customer base, and applications across cancer research, drug discovery, biomarker identification, precision medicine, tissue mapping, and disease diagnostics.

Key Multimodal Spatial Biology Analysis Platforms Companies:

The following key companies have been profiled for this study on the multimodal spatial biology analysis platforms market.

• 10x Genomics, Inc.

• Bruker Spatial Biology (Bruker Corporation)

• Lunaphore Technologies SA (acquired by Bio-Techne)

• Quanterix

• Vizgen Corp.

• Standard BioTools

• Leica Microsystems (acquired by Danaher Corporation)

• Miltenyi Biotec

• STOmics Tech (acquired by MGI tech GmbH)

• Illumina, Inc.

• RareCyte, Inc.

• Singular Genomics Systems, Inc.

• Element Biosciences

• Curio Bioscience (acquired by Takara Bio Inc.)

• Stellaromics

Competitive Benchmarking

Recent Developments:

• In February 2026, Bruker Corporation launched the CellScape XR spatial proteomics platform, designed to enable highly multiplexed protein detection and quantitative tissue analysis. The platform strengthens Bruker’s spatial biology portfolio by supporting spatial biomarker discovery, translational research, and diagnostic assay development.

“We are deploying the CellScape platform to develop translational predictive and prognostic spatial-omics panels and AI-informed signatures across multiple solid tumor indications. The quantitative consistency and throughput of the CellScape platform allows us to evaluate spatially resolved biomarkers across large patient cohorts, which is essential for building clinically meaningful prognostic assays. Our long-term goal is to translate this work to the clinic, and CellScape XR provides the technical foundation to get there.”

- Niclas C. Blessin MD, Assistant Professor of Pathology at UKSH.

• In April 2024, Standard BioTools Inc. introduced new high-throughput imaging capabilities for its Hyperion XTi Imaging System, including three imaging modes for rapid tissue analysis and an automated slide loader capable of processing up to 40 slides. Powered by Imaging Mass Cytometry technology, the system enables simultaneous detection of more than 40 protein and RNA markers, supporting spatial biomarker discovery, tumor microenvironment characterization, immunology research, and drug development.

“The innovations we are putting forth demonstrate our commitment to providing the best, most reliable and essential tools for our customers. These new capabilities further facilitate the use of IMC across any phase of research, helping establish the technology as an unrivaled leader in spatial proteomics. Now researchers can capture all markers simultaneously in a single scan and generate confident data from 40-plus protein markers on 40 slides in 24 hours, with a fully optimized end-to-end workflow.”

- Michael Egholm, PhD, President and CEO of Standard BioTools

• In March 2024, 10x Genomics, Inc. commercially launched the Visium HD Spatial Gene Expression assay, enabling whole-transcriptome profiling of formalin-fixed, paraffin-embedded (FFPE) tissue samples at single-cell-scale resolution. The platform integrates spatial gene expression data with histological imaging and bioinformatics, strengthening applications in tissue mapping, cancer research, and spatial transcriptomics.

"Visium HD is a game-changer for spatial discovery research, and our team couldn't be more proud and excited to get this long-awaited product into the hands of our customers. This is the most requested product in our history, and I can't think of a better example of how 10x listens to our customers and takes on the hardest development challenges to have the biggest impact on scientific research. We're confident researchers will agree Visium HD was well worth the wait."

- Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics

Multimodal Spatial Biology Analysis Platforms Market Report Scope

Multimodal Spatial Biology Analysis Platforms Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global multimodal spatial biology analysis platforms market on the basis of offering, modality combination, technology, sample type, application, end use and region

• Offering Outlook (Revenue, USD Million, 2021 - 2033)

  • Consumables & Reagents

  • Instruments

  • Services

  • Software

• Modality Combination Outlook (Revenue, USD Million, 2021 - 2033)

  • Transcriptomics + Proteomics

  • Transcriptomics + Genomics / Epigenomics

  • Proteomics + Metabolomics / Lipidomics

  • Others

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Imaging-based

  • Sequencing-based

  • Mass Spectrometry-based

  • Others

• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)

  • FFPE Tissue

  • Fresh Frozen Tissue

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Immunology & Inflammation

  • Neuroscience

  • Infectious Diseases

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Academic & Translational Research Institutes

  • Pharmaceutical & Biotechnology Companies

  • CROs & Service Providers

  • Hospitals & Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The multimodal spatial biology analysis platforms market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each multimodal spatial biology analysis platforms segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations